Three-year data from the BE RADIANT trial demonstrate that bimekizumab provides rapid and lasting improvements in patient-reported symptoms and quality of life for individuals with moderate-to-severe plaque psoriasis.
Findings from the 48-week double-blind phase and a 96-week open-label extension (OLE) offer up to three years of treatment data. In the initial randomized period, patients received either bimekizumab or secukinumab. Patient-reported outcomes, including itching, skin pain, and scaling, were assessed alongside psoriasis severity and quality of life.
Bimekizumab showed notable symptom relief by Week 4, with significantly higher percentages of patients reporting no itching, skin pain, or scaling compared to secukinumab. These benefits persisted at one year.
By one year, bimekizumab also led to higher rates of complete skin clearance combined with minimal impact on quality of life. At Week 4, 11.5% of bimekizumab-treated patients achieved minimal disease activity (PASI=0 and DLQI 0/1), compared with 4.6% in the secukinumab arm. By Year 1, this figure rose to 61.7% versus 42.7%.
At the end of the double-blind phase, patients on continuous bimekizumab treatment maintained high response rates. Those switching from secukinumab to bimekizumab experienced increased efficacy. By Year 3, high response rates were sustained in both groups, indicating durable clinical efficacy translating into meaningful and lasting improvements in symptoms and health-related quality of life.